Spiration competitors

Mr. Norman D. Schwartz is Chairman of the Board, President, Chief Executive Officer of Bio Rad Laboratories Inc. Mr. Schwartz has been President and Chief Executive Officer since 2003 and Chairman of the Board since 2012. He was Vice President from 1989 to 2002, Group Manager, Life Science, from 1997 to 2002 and Group Manager, Clinical Diagnostics, from 1993 to 1997.

Results-focused senior executive whose strategic vision, leadership and commitment to success consistently led to dynamic gains in revenue, profit, operational performance and competitive advantage in US and global markets. Leverages instinctive ability to zero in on product and market potential to achieve objectives in start-up, turnaround and growth environments.Selected Achievements:Led $400 million division to record growth in worldwide sales and profit, with 14% year-over-year revenue gains and 10 point improvement in the bottom line.Key member of executive team that negotiated the $2.2 billion acquisition of Gyrus ACMI by Olympus Corporation.Built US division to $96.6 million in sales with average annual revenue growth of 35% for 3 consecutive years.Strategic forward thinker - initiated and spearheaded a comprehensive $700 million business restructuring to comply with changing healthcare laws and regulations while concurrently streamlining process, driving productivity and increasing customer satisfaction. The initiative resulted in a 15% reduction in expenses and a 5% revenue increase.

Mr. Matthew T. Plavan is a Chief Executive Officer at THERMOGENESIS HOLDINGS, INC. and is based in United States.

With a proven track record of bringing game-changing technologies to the market, Mr. Shamir joined Luminex Corporation as President, Chief Executive Officer, and Board Member in 2014. From 2006 to 2014, Mr. Shamir served as President and CEO of Given Imaging, a developer, manufacturer, and marketer of diagnostic products for the visualization and detection of disorders of the gastrointestinal tract, which was acquired by Covidien PLC in early 2014. Mr. Shamir currently serves on the board of directors of Exalenz Bioscience Ltd. (TASE: EXEN). He has previously served as a Board Member at Scitex Corporation, Cogentix Medical (NASDAQ: CGNT), recently acquired by Laborie Medical Technologies, and invendo medical GmBH, now part of Ambu. Mr. Shamir holds a Bachelor of Science from the Hebrew University of Jerusalem and a Masters of Public Administration from Harvard University.

Dr. Singh was elected President and Chief Executive Officer of PerkinElmer effective December 30, 2019, and appointed to our board of directors in August 2019. Previously Dr. Singh was the President and Chief Operating Officer of the Company since January 2019. Dr. Singh joined PerkinElmer as the President of our Diagnostics business in May 2014. He was elected Senior Vice President in September 2016 and Executive Vice President in March 2018. Prior to joining PerkinElmer, Dr. Singh was General Manager of GE Healthcare’s Women’s Health business from 2012 to 2014, with responsibility for its mammography and bone densitometry businesses. Before that, Dr. Singh held senior executive level roles in strategy, business development and mergers & acquisitions at both GE Healthcare and Philips Healthcare. Earlier in his career, he held leadership roles of increasing responsibility at DuPont Pharmaceuticals and subsequently Bristol-Myers Squibb Medical Imaging, which included managing the Asia Pacific and Middle East region. Dr. Singh holds a doctoral degree in chemistry from the University of Missouri-Columbia and a Master of Business Administration from Northeastern University. His research work has resulted in several issued patents and publications in peer reviewed journals. Dr. Singh has more than twenty-five years of leadership experience with global innovators in healthcare technology. He has spent the most recent six years developing unique insights into both our business and our opportunities for continued growth. Dr. Singh brings to our board a detailed understanding of the core technologies that we utilize and the operational strategies available to us as we continue to focus on innovating for a healthier world.

David Andrew Fischel (born 1 April 1958) is a British businessman. He was formerly the chief executive of Intu Properties Group plc, a British shopping centre management and development company between 2001 and 2019.

Constance Ryan is a President and Chief Executive Officer at Streck and is based in United States. She works or has worked at Streck.

Stephen Turner is Chief Executive Officer and Chairman of the Board, positions he has held since founding the company in July, 2001. From 1999 to 2001 he served as President and CEO of Quorum Sciences, Inc. From 1984 to 1997 he was President and CEO of Oncor, Inc. He founded Bethesda Research Laboratories, Inc. in 1975 and served as its Chairman and CEO from 1975 to 1983, at which time BRL became the molecular biology division of Life Technologies, Inc. Prior to commencing his career in biotechnology, Mr. Turner held the position of Director of Marketing for the Clinical Microbiology Division of Becton, Dickinson & Co. He received his B.A. from Stanford University in 1967. In 1994 he received the Ernst & Young Entrepreneur of the Year Award in Life Sciences for the Washington D.C. Region.